Studies related to Weight and Lactobacillus reuteri

Evaluation Of Clinical Safety And Tolerance Of A Lactobacillus Reuteri NCIMB 30242 Supplement Capsule: A Randomized Control Trial

Effect None
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 124
Gender Both Genders
Age Range 30-44, 45-64
Body Types Overweight
Notes for this study:
Supplementation of _l. reuteri_ NCIMB 30242 at 2.9x10^9^ CFU twice daily in otherwise healthy hypercholesteromic adults for nine weeks did not appear to confer any significant toxic effects relative to placebo.

LDL cholesterol appeared to be reduced 11.7% with supplementation, but most other parameters were unchanged.
Funding issues for this study:
Funding provided by Micropharma, producer of Cardioviva

Improvement Of Digestive Health And Reduction In Proteobacterial Populations In The Gut Microbiota Of Cystic Fibrosis Patients Using A Lactobacillus Reuteri Probiotic Preparation: A Double Blind Prospective Study

Effect None
Trial Design Double blind
Trial Length 6+ Months
Number of Subjects 30
Gender Both Genders
Age Range 7-12, 13-17, 18-29, 30-44
Notes for this study:
DSM 17938 at 10^8^ CFU daily for six months noted that, in a double blind crossover design, that persons with cystic firbosis experienced a betterment of intestinal discomfort associated with beneficial changes in the gut microflora (which is inherently altered from the norm in cystic fibrosis). Despite benefits to intestinal discomfort, no overall changes were noted on the SF-12 (general health survey).

Lung power and inflammatory/antiinflammatory cytokines were all unaffected, although fecal calprotectin (biomarker of intestinal inflammation) was reduced by 40%.

Safety And Tolerance Of Lactobacillus Reuteri Supplementation To A Population Infected With The Human Immunodeficiency Virus

Effect None
Trial Design Double blind
Trial Length 2-4 Weeks
Number of Subjects 39
Gender Both Genders
Age Range 18-29, 30-44, 45-64
Body Types Average
Notes for this study:
Supplementation of _l. reuteri_ at 10^10^ CFU in two divided doses a day for three weeks in persons with HIV failed to significantly influence any observed biochemical parameter to a level which was deemed practically relevant, with most parameters also failing to be significantly influenced.